Sandoz to market authorized generic version of Adderall XR
PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.
Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).
Under the five-year agreement, which became effective Sunday, Sandoz will begin marketing the product starting in July 2016. Shire will manufacture the drug, while Sandoz will market it and provide royalties on sales to Shire.
Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a contract between the branded drug’s manufacturer and a third-party company.
Study finds better adherence among patients in medication-synchronization programs
WASHINGTON — Patients who received appointment-based medication synchronization were up to six times more likely to adhere to their therapies than those who didn’t, according to a study of patients at rural Thrifty White Pharmacy locations in the Midwest published in the Journal of the American Pharmacists Association.
The study, which appears in JAPhA‘s November/December issue, found that patients in the appointment-based medication synchronization, or ABMS group, were 3.4-6.1 times more likely to be adherent, while those in the control group were 52% to 73% more likely to stop taking chronic medications over the course of a year. Overall, the patients in the ABMS program showed adherence rates of 66.1% to 75.5% over the year, compared with 37% to 40.8% among control patients. The study took place in rural pharmacies in the Midwest between June 30, 2011 and Oct. 31. 2012.
"This research shows appointment-based medication synchronization to be one of the most effective interventions available to help patients take their medications," lead study author and Virginia Commonwealth University pharmacy professor David Holdford said. "Widespread implementation in pharmacies across the United States can have a major impact on patient health."
New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
CAMP HILL, Pa. – Rite Aid has promoted Karen Staniforth, VP pharmacy for the chain’s mid-Atlantic division, to group VP pharmacy initiatives and clinical services, the company said Monday.
In the new position, Staniforth will oversee Rite Aid’s strategy around the Wellness Ambassadors, specially trained staff who work in its Wellness stores, answering customers’ questions about health and wellness products and directing them to the pharmacy as needed. She will report to SVP pharmacy Dan Miller.
"Throughout her career, Karen has garnered critical knowledge and experience across several functional areas of the chain drug industry, making her a true asset to our company," Miller said. "Her valuable insights will guide us as we work to advance our clinical services and Wellness Ambassador programs, helping us highlight the expertise of our more than 11,000 pharmacists and providing superior care and health outcomes for our patients nationwide."
Staniforth started her pharmacy career in 1982 in Johannesburg and became regional sales manager for Novartis Pharmaceuticals in 1991, overseeing retail sales operations for the Swiss drug maker in Cape Town, South Africa. She began working for Rite Aid in 1998 as a graduate pharmacy intern after moving to the United States.